M. Evanchik

发表

Structure-activity relationship (SAR) of the α-amino acid residue of potent tetrahydroisoquinoline (THIQ)-derived LFA-1/ICAM-1 antagonists.

M. Arkin, S. Prabhu, W. Shen, 2011, Bioorganic & medicinal chemistry letters.

Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists.

M. Arkin, K. Huen, B. Cunningham, 2010, Bioorganic & medicinal chemistry letters.

Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.

E. Schiff, T. Hassanein, M. Yuen, 2022, Journal of hepatology.

Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy

S. Markova, J. Driscoll, P. Vicat, 2020, Xenobiotica; the fate of foreign compounds in biological systems.

Abstract 20593: In vivo Cardiac Effects of Mavacamten (MYK-461): Evidence for Negative Inotropy and Improved Compliance

Eric M. Green, Y. Ueyama, L. Lucats, 2017 .

A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy

S. Markova, Eric M. Green, P. Pascoe, 2016, PloS one.

Metabolism of (+)-1,4-Dihydro-7-(trans-3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic Acid (Voreloxin; Formerly SNS-595), a Novel Replication-Dependent DNA-Damaging Agent

Joshua C. Yoburn, U. Hoch, J. Silverman, 2009, Drug Metabolism and Disposition.

Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.

M. Arkin, S. Prabhu, W. Shen, 2012, ACS medicinal chemistry letters.

Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study

T. Hassanein, M. Yuen, D. J. Kim, 2022, Journal of viral hepatitis.

A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice

Christine E. Seidman, James A. Spudich, Robert S. McDowell, 2016, Science.

Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation.

M. Sivaraja, R. Mcdowell, C. Zaharia, 2013, ACS medicinal chemistry letters.

Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.

R. Fucini, I. C. Choong, Joshua C. Yoburn, 2008, Bioorganic & medicinal chemistry letters.

Phase 1 trial of SNS-314, a novel selective inhibitor of aurora kinases A, B, and C, in advanced solid tumor patients

R. Advani, H. Hurwitz, C. Verschraegen, 2008 .

SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo

R. Fucini, A. Howlett, Brian J. Belmont, 2010, Cancer Chemotherapy and Pharmacology.

Abstract 16842: Obstructive Hypertrophic Cardiomyopathy: Initial Single Ascending Dose Data in Healthy Volunteers and Patients

E. Ashley, K. Mahaffey, J. Ritter, 2016 .

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.

E. Schiff, T. Hassanein, M. Yuen, 2022, Journal of hepatology.

In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

S. Markova, J. Driscoll, R. Dick, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

283 POSTER Phase 1 trial of SNS-314, a novel selective inhibitor of Aurora kinases A, B, and C, in advanced solid tumor patients

R. Advani, H. Hurwitz, C. Verschraegen, 2008 .